Citi lowered the firm’s price target on 2seventy Bio to $9 from $11 and keeps a Buy rating on the shares. The analyst continues to anticipate Abecma revenue growth in 2024 driven by label expansion, but acknowledges the near-term uncertainty for Abecma’s commercial performance. The firm now sees a more gradual launch.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on TSVT: